Heart failure is defined as when the heart cannot supply enough blood to the body to meet its demands. The reduction in pumping capacity is the consequence of damage to the cardiac muscle from a variety of causes, such as a heart attack, chronic hypertension and infections of the myocardium. This damage causes a reduction in the pumping efficiency of the heart producing a reduction in cardiac output. The body responds to this by activating compensatory mechanisms primarily through activation of the sympathetic nervous system. This activation attempts to boost cardiac output by increasing heart rate and raising blood pressure through vasoconstriction and increasing fluid volume. Whilst this response does succeed in increasing blood supply through in-creasing the rate and force of contraction, it simultaneously increases the overall workload on the heart, which over time damages the heart further. A vicious circle of reduced cardiac output, activation of compensatory mechanisms and increasing damage to the heart is created and thus heart failure is a chronic progressive disease. Once the cycle of heart failure is established, current therapies can do little to prevent disease progression. Even on optimal therapy (OMT) mortality rates are 50% at five years from diagnosis, which is considerably worse than most forms of cancer. Patients experience increasing disability as the function of the heart declines; breathlessness and fatigue on exertion is eventually experienced even at rest, with hospitalisation and hospice care being inevitable. Ceryx’scardiac rhythm management device is unique is being able to boost cardiac output while simultaneously reducing cardiac workload. The device breaks the cycle of heart failure and offers the world’s first curative therapy for for heart failure.
Heart Failure Statistics
20 million people suffer with heart failure in US and EU
50% are dead within 5 years
$50Bn per year is spent in the US alone managing the condition